Alexion to Pick Goldman to Advise on Roche Offer?

Your next video will start in

Recommended Videos

  • Info

  • Comments


July 30 (Bloomberg) -- Alexion Pharmaceuticals, the drugmaker whose blood-disease treatment is among the world’s most expensive medicines, engaged Goldman Sachs as an adviser as it prepares for a possible takeover offer from Roche, said people with knowledge of the matter. Cristina Alesci reports on Bloomberg Television's "Money Moves." (Source: Bloomberg)

We have news on the drug manufacturer who is responsible for the world's most expensive medicine.

They have hired goldman sachs.

What is the back story?

What's this would be a huge deal, 22 billion dollars.

Clearly a big number.

We don't know whether they are planning to go hostile and take this directly to shareholders or present a deal that is acceptable to management.

Either way, they have been approached by epsilon and they will be hired by defense or to negotiate a deal.

This is a company that generates $1.1 billion from a very expensive blood disease and education.

This goes along with the theme of more mergers and healthcare.

Banker that i speak to says that this will be hot.

This comes on the deal -- on the heels of the deal from amgen.

When we talk about roche, the story of that company really speaks to the theme of the whole industry.

All of these drugmakers are coming under intense pressure to diversify their product line.

They have had some problems developing drugs outside of their traditional cancer line.

They had to halt development on the cholesterol drug and now it has to go outside for growth.

We will keep an eye on this.

This text has been automatically generated. It may not be 100% accurate.


BTV Channel Finder


ZIP is required for U.S. locations

Bloomberg Television in   change